Skip to main content
Patient Information For US Residents Only

What is INBRIJA®?

INBRIJA, the only inhaled levodopa, starts working in as little as
10 minutes

10 minutes

For people taking carbidopa/levodopa for Parkinson's and experiencing the return of symptoms between regular doses of medication, adding INBRIJA can help.

In a large clinical trial, INBRIJA started improving motor symptoms in as soon as 10 minutes.

Rescue the moments in your day with INBRIJA

Inbrija Inhaler

INBRIJA is an inhaled form of the levodopa in your regular carbidopa/levodopa Parkinson’s medication. INBRIJA does not replace your regular carbidopa/levodopa medicine.

INBRIJA can help manage the return of symptoms.

INBRIJA may start to work in as soon as 10 minutes. In a large study, significant relief in motor symptoms was seen in 30 minutes of taking INBRIJA.

INBRIJA is orally inhaled.

INBRIJA allows levodopa to enter the lungs. From the lungs, levodopa gets into the blood and then to the brain. INBRIJA does not depend on the digestive tract to be absorbed.

  • Before using INBRIJA, tell your healthcare provider if you have asthma, chronic obstructive pulmonary disease (COPD), or any chronic lung disease.
  • Tell your healthcare provider if you experience bronchospasm. People with asthma, COPD, or other lung diseases may wheeze or have difficulty breathing after inhaling INBRIJA. If this occurs, stop taking INBRIJA and seek immediate medical attention.

INBRIJA is for use as needed.

Take it as prescribed when symptoms of your OFF periods start to return (1 dose per OFF period, no more than 5 doses a day).

  • Do not stop taking your regular Parkinson's medicine. INBRIJA does not replace your regular carbidopa/levodopa medicine.

INBRIJA is lightweight and portable.

INBRIJA is easy to carry with you. Store your INBRIJA at room temperature 68°F to 77°F (20°C to 25°C) in a dry place.

  • Keep the capsules in their foil (blister) packages until just before you're ready to use them.
Talk to your doctor about a free trial* of INBRIJA

*Limitations and restrictions apply.

Inbrija Inhaler

Selected Important Safety Information

Tell your healthcare provider if you experience the following side effects:

  • falling asleep during normal daily activities with or without warning. If you become drowsy, do not drive or do activities where you need to be alert. Chances of falling asleep during normal activities increases if you take medicine that cause sleepiness.
  • withdrawal-emergent hyperpyrexia and confusion (fever, stiff muscles, or changes in breathing and heartbeat) if you suddenly stop using INBRIJA or carbidopa/levodopa, or suddenly lower your dose of carbidopa/levodopa.
  • low blood pressure when standing up (that may be with dizziness, fainting, nausea, and sweating). Get up slowly after sitting/lying down.
  • hallucinations and other psychosis – INBRIJA may cause or worsen seeing/hearing/believing things that are not real; confusion, disorientation, or disorganized thinking; trouble sleeping; dreaming a lot; being overly suspicious or feeling people want to harm you; acting aggressive; and feeling agitated/restless.
  • unusual uncontrollable urges such as gambling, binge eating, shopping, and sexual urges has occurred in some people using medicine like INBRIJA.
  • uncontrolled, sudden body movements (dyskinesia) may be caused or worsened by INBRIJA. INBRIJA may need to be stopped or other Parkinson’s medicines may need to be changed.
  • bronchospasm – people with asthma, COPD, or other lung diseases may wheeze or have difficulty breathing after inhaling INBRIJA. If this occurs, stop taking INBRIJA and seek immediate medical attention.
  • increased eye pressure in patients with glaucoma. Your healthcare provider should monitor this.
  • changes in certain lab values including liver tests

Please see below for additional Important Safety Information.

Common Questions

Show Answers

Will I be able to use INBRIJA while I'm experiencing the return of symptoms?

Most people in clinical trials were able to use INBRIJA. In fact, 99.8% (628 out of 629) of people with Parkinson’s who participated in two clinical trials, after instruction, were able to use INBRIJA in an OFF period.

Remember to take an INBRIJA dose as soon as you feel Parkinson’s symptoms start to return.

What are the most common side effects of INBRIJA?

The most common side effects of INBRIJA are cough, upper respiratory tract infection, nausea, and change in the color of saliva or spit.

Why doesn’t INBRIJA replace my other Parkinson’s medications?

INBRIJA is orally inhaled levodopa used as needed to treat the return of your Parkinson’s symptoms and is used as an add‑on therapy only, which means it does not replace your usual carbidopa/levodopa regimen. INBRIJA has not been studied in patients not taking their regular carbidopa/levodopa medicine and will not work without it.

See full list of
common questions

Have questions?

Contact us at 1‑833‑INBRIJA

INBRIJA® Indication

Treats OFF periods in adults taking carbidopa/levodopa (CD/LD). INBRIJA doesn’t replace CD/LD.

Important Safety Information

Don’t use if you have taken a nonselective monoamine oxidase inhibitor (eg, phenelzine, tranylcypromine) within the last 2 weeks.

Indication

INBRIJA is a prescription medicine used when needed for OFF episodes in adults with Parkinson’s treated with regular carbidopa/levodopa medicine. INBRIJA does not replace regular carbidopa/levodopa medicine.

Important Safety Information

Do not use INBRIJA if you take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last 2 weeks.

Before using INBRIJA, tell your healthcare provider about your medical conditions, including:

  • asthma, chronic obstructive pulmonary disease (COPD), or any chronic lung disease
  • daytime sleepiness, sleep disorders, sleepiness/drowsiness without warning, or use of medicine that increases sleepiness, including antidepressants or antipsychotics
  • dizziness, nausea, sweating, or fainting when standing up
  • abnormal movement (dyskinesia)
  • mental health problems such as hallucinations or psychosis
  • uncontrollable urges like gambling, sexual urges, spending money, or binge eating
  • glaucoma
  • pregnancy or plans to become pregnant. It is unknown if INBRIJA will harm an unborn baby.
  • breastfeeding or plans to breastfeed. Levodopa can pass into breastmilk and it is unknown if it can harm the baby.

Tell your healthcare provider if you take:

  • MAO-B inhibitors
  • dopamine (D2) antagonists (including phenothiazines, butyrophenones, risperidone, metoclopramide)
  • isoniazid
  • iron salts or multivitamins that contain iron salts

Do not drive, operate machinery, or do other activities until you know how INBRIJA affects you. Sleepiness and falling asleep suddenly can happen as late as a year after treatment is started.

Tell your healthcare provider if you experience the following side effects:

  • falling asleep during normal daily activities with or without warning. If you become drowsy, do not drive or do activities where you need to be alert. Chances of falling asleep during normal activities increases if you take medicine that cause sleepiness.
  • withdrawal-emergent hyperpyrexia and confusion (fever, stiff muscles, or changes in breathing and heartbeat) if you suddenly stop using INBRIJA or carbidopa/levodopa, or suddenly lower your dose of carbidopa/levodopa.
  • low blood pressure when standing up (that may be with dizziness, fainting, nausea, and sweating). Get up slowly after sitting/lying down.
  • hallucinations and other psychosis – INBRIJA may cause or worsen seeing/hearing/believing things that are not real; confusion, disorientation, or disorganized thinking; trouble sleeping; dreaming a lot; being overly suspicious or feeling people want to harm you; acting aggressive; and feeling agitated/restless.
  • unusual uncontrollable urges such as gambling, binge eating, shopping, and sexual urges has occurred in some people using medicine like INBRIJA.
  • uncontrolled, sudden body movements (dyskinesia) may be caused or worsened by INBRIJA. INBRIJA may need to be stopped or other Parkinson’s medicines may need to be changed.
  • bronchospasm – people with asthma, COPD, or other lung diseases may wheeze or have difficulty breathing after inhaling INBRIJA. If this occurs, stop taking INBRIJA and seek immediate medical attention.
  • increased eye pressure in patients with glaucoma. Your healthcare provider should monitor this.
  • changes in certain lab values including liver tests

The most common side effects of INBRIJA are cough, upper respiratory tract infection, nausea, and change in the color of saliva or spit.

Do not orally inhale more than 1 dose (2 capsules) for any OFF period. Do not take more than 5 doses (10 capsules) in a day.

Please see the Patient Information Leaflet.